Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months and following Kisqali® (ribociclib) treatment completion by 78.3% of patients.
Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals.
Alveolus Bio Enters Into Strategic Collaboration with BiomEdit Read More »
For the second time in as many days, Merck has reported a Phase III failure for its blockbuster PD-1 inhibitor Keytruda, this time as a first-line treatment with Eisai’s Lenvima for cancer in the uterus lining.
Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study Read More »
Results from a Phase III trial showed the combination improves progression-free survival compared to chemotherapy when used as a first-line treatment in metastatic colorectal cancer.
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer Read More »
The biopharma industry is projected to raise $24 billion this year, a steep decline from the “high-water marks” of 2020 through 2022, according to a new report from market data firm PitchBook.
Biopharma Funding, Deals Fall Sharply in 2023 in ‘Strategic’ Shift: PitchBook Read More »
FluoGuide A/S, a pioneer in the cutting-edge field of precision cancer surgery, announced the status of the exercised warrants, issued in connection with the directed share issue in July this year, raising SEK 12 million.
FluoGuide Raises SEK 12 million through Exercise of Warrants Read More »
TILT Biotherapeutics presented safety and efficacy data from its international Phase I trial in patients with metastatic melanoma, in an oral presentation at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announces its revised outlook for 2024 and reflects on recent progress.
EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of FDA “Fast-Track” designation for its pancreatic cancer therapeutic.
Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation will be presented at the 65th American Society of Hematology Annual Meeting held from December 9-12, 2023, in San Diego, California, USA.
